The FDA approved Sanofi’s daily diabetes drug Toujeo Wednesday, but the new treatment does not appear to pack a profile that will pull payers or physicians away from Lantus to generic-free Toujeo.
The product site for Sanofi-Aventis’s insulin injection Lantus received the highest mark in terms of consumer satisfaction, according to a Manhattan Research study. The website (which features ...
The FINANCIAL — Merck on June 13 announced results from two Phase 3 studies evaluating MK-1293, Merck’s investigational, follow-on biologic insulin glargine candidate for the treatment of people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results